Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have received a consensus recommendation of “Moderate Buy” from the nineteen research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $187.39.

Several equities analysts have recently weighed in on the company. Morgan Stanley restated an “overweight” rating and issued a $165.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 21st. BMO Capital Markets increased their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Sarepta Therapeutics in a report on Thursday, September 19th. Needham & Company LLC reiterated a “buy” rating and issued a $235.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, June 27th. Finally, Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and lowered their price objective for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th.

Insider Transactions at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of SRPT. Principal Securities Inc. acquired a new position in Sarepta Therapeutics in the fourth quarter valued at about $26,000. Dimensional Fund Advisors LP raised its position in shares of Sarepta Therapeutics by 10.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock valued at $21,621,000 after buying an additional 20,923 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 125.3% during the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after acquiring an additional 27,549 shares during the period. Norges Bank bought a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $80,697,000. Finally, UBS Group AG increased its stake in Sarepta Therapeutics by 26.5% in the fourth quarter. UBS Group AG now owns 276,276 shares of the biotechnology company’s stock valued at $26,641,000 after acquiring an additional 57,805 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Down 0.2 %

Shares of Sarepta Therapeutics stock opened at $124.53 on Monday. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. The business’s 50 day simple moving average is $134.99 and its 200 day simple moving average is $132.70. The firm has a market cap of $11.77 billion, a PE ratio of 1,132.09 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same quarter in the prior year, the company posted ($0.27) earnings per share. The firm’s revenue was up 38.9% on a year-over-year basis. On average, analysts predict that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.